



Universiteit
Leiden
The Netherlands

Improving therapy options for patients with metastatic castrate-resistant prostate cancer

Wissing, M.D.

Citation

Wissing, M. D. (2014, September 17). *Improving therapy options for patients with metastatic castrate-resistant prostate cancer*. Retrieved from <https://hdl.handle.net/1887/28765>

Version: Corrected Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/28765>

Note: To cite this publication please use the final published version (if applicable).

Cover Page



Universiteit Leiden



The handle <http://hdl.handle.net/1887/28765> holds various files of this Leiden University dissertation.

Author: Wissing, Michel Daniël

Title: Improving therapy options for patients with metastatic castrate-resistant prostate cancer

Issue Date: 2014-09-17

Propositions

1. Analysis of Functional Annotation can be used to create a rationale for novel combination therapies, and therefore may prevent unnecessary trial-and-error combination studies (this thesis).
2. Preclinical research suggests that prostate cancer patients may benefit from treatment with antimetabolic agents such as aurora kinase inhibitors and polo-like kinase 1 inhibitors, particularly in combination with other therapies (this thesis).
3. Retrospective clinical studies suggest that patients with metastatic castrate-resistant prostate cancer who responded well to docetaxel treatment may need to be treated with cabazitaxel before abiraterone as second-line therapy when the patient's condition allows for additional chemotherapy (this thesis).
4. Eg5 is a marker for docetaxel response and tumor aggressiveness in prostate cancer patients (this thesis).
5. Preclinical research indicates that irinotecan and cetrimonium bromide may prevent or reduce prostate cancer metastases by selectively targeting prostate cancer cells deficient in the metastasis suppressor gene N-myc downregulated gene 1 (this thesis).
6. A current priority in prostate cancer research is to identify markers predicting disease and therapy outcome.
7. The United States Food and Drug Administration and similar institutions need to involve cost of a cancer therapy in their decision to approve new drugs.
8. Despite the introduction of various targeted therapies, chemotherapy remains of importance for the treatment of patients with metastatic castrate-resistant prostate cancer.
9. The approval of radium-223 for the treatment of bone metastases proves that targeting of metastases is an effective antitumor strategy in prostate cancer.
10. The roots of education are bitter, but the fruit is sweet – Aristoteles (384-322 BC)
11. The good physician treats the disease; the great physician treats the patient who has the disease – William Osler (1849-1919)
12. Medicine sometimes snatches away health, sometimes gives it – Ovidius (43BC-17AD)